Skip to main content

Regnante Keith's Form 4 filing

Keros Therapeutics, Inc. (KROS) · filed Jan 8, 2024

Accession no.
0001209191-24-001155
Filed
Jan 8, 2024
Trade date
Nov 4, 2023-Jan 4, 2024
Filing delay
65 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.81M. It was filed 65 days after the trade, past the 2-business-day deadline.

This filing was later replaced by the amendment 0001415889-25-002024 (Jan 24, 2025). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Regnante KeithCIK 0001682068Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 4, 2023Common StockMOption exerciseAcquired+40,000$16.00+$640,00040,000Direct
Nov 4, 2023Common StockSSaleDisposed−40,000$45.29−$1,811,6000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 4, 2024Common StockMOption exerciseDisposed−40,000$0.00$053,622Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)